KRAS and non-small cell lung carcinoma: Recent results from the phase 2 trials CodeBreaK 100 and KRYSTAL-1 (12, 13) led to FDA approval of KRAS G12C selective inhibitors, i.e., sotorasib in May 2021 and the new drug application for the use of adagrasib in February 2022, for patients with pretreated KRAS G12C-NSCLC (14, 15).